These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2002459)

  • 21. Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy.
    Singhal D; Anderson BD
    J Pharm Sci; 1998 May; 87(5):578-85. PubMed ID: 9572908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Probing the active site of adenosine deaminase by a pH responsive fluorescent competitive inhibitor.
    Caiolfa VR; Gill D; Parola AH
    Biophys Chem; 1998 Jan; 70(1):41-56. PubMed ID: 9474762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of lymphocyte-mediated cytolysis and cyclic AMP phosphodiesterase by erythro-9-(2-hydroxy-3-nonyl)adenine.
    Duncan GS; Wolberg G; Schmitges CJ; Deeprose RD; Zimmerman TP
    J Immunopharmacol; 1982; 4(1-2):79-100. PubMed ID: 6296234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the chiral isomers of erythro- and threo-9-(2-hydroxy-3-nonyl)adenine on purine metabolism in sarcoma 180 cells.
    Chen SF; Stoeckler JD; Choi HS; Burgess FW; Marcaccio EJ; Steen PA; Berman SF; Parks RE; Panzica RP; Abushanab E
    Biochem Pharmacol; 1982 Dec; 31(24):3955-60. PubMed ID: 7159473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation.
    Kayhan N; Funke B; Conzelmann LO; Winkler H; Hofer S; Steppan J; Schmidt H; Bardenheuer H; Vahl CF; Weigand MA
    Crit Care; 2008; 12(5):R125. PubMed ID: 18847498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of adenosine deaminase with inhibitors. Chemical modification by diethyl pyrocarbonate.
    Mardanyan SS; Sharoyan SG; Antonyan AA; Lupidi G; Cristalli G
    Biochemistry (Mosc); 2002 Jul; 67(7):770-7. PubMed ID: 12139475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythro-9-(2-hydroxy-3-nonyl)adenine as a specific inhibitor of herpes simplex virus replication in the presence and absence of adenosine analogues.
    North TW; Cohen SS
    Proc Natl Acad Sci U S A; 1978 Oct; 75(10):4684-8. PubMed ID: 216993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythro- and threo-2-hydroxynonyl substituted 2-phenyladenines and 2-phenyl-8-azaadenines: ligands for A1 adenosine receptors and adenosine deaminase.
    Biagi G; Giorgi I; Livi O; Pacchini F; Rum P; Scartoni V; Costa B; Mazzoni MR; Giusti L
    Farmaco; 2002 Mar; 57(3):221-33. PubMed ID: 11989801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of human lymphocyte DNA and protein synthesis in vitro by adenosine and eight modified adenine nucleosides in the presence or in the absence of adenosine deaminase inhibitors, 2'-deoxycoformycin (DCF) and erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA).
    Ratech H; Kuritsky L; Thorbecke GJ; Hirschhorn R
    Cell Immunol; 1982 Apr; 68(2):244-51. PubMed ID: 6980056
    [No Abstract]   [Full Text] [Related]  

  • 30. Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells.
    Burton P; Adams DR; Abraham A; Allcock RW; Jiang Z; McCahill A; Gilmour J; McAbney J; Kaupisch A; Kane NM; Baillie GS; Baker AH; Milligan G; Houslay MD; Mountford JC
    Biochem J; 2010 Dec; 432(3):575-84. PubMed ID: 20923411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition.
    Bessodes M; Bastian G; Abushanab E; Panzica RP; Berman SF; Marcaccio EJ; Chen SF; Stoeckler JD; Parks RE
    Biochem Pharmacol; 1982 Mar; 31(5):879-82. PubMed ID: 7082355
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardioprotection with adenosine metabolism inhibitors in ischemic-reperfused mouse heart.
    Peart J; Matherne GP; Cerniway RJ; Headrick JP
    Cardiovasc Res; 2001 Oct; 52(1):120-9. PubMed ID: 11557240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA).
    Lum CT; Schmidtke JR; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473
    [No Abstract]   [Full Text] [Related]  

  • 34. Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines.
    Bastian G; Bessodes M; Panzica RP; Abushanab E; Chen SF; Stoeckler JD; Parks RE
    J Med Chem; 1981 Dec; 24(12):1383-5. PubMed ID: 7310814
    [No Abstract]   [Full Text] [Related]  

  • 35. Endogenous adenosine modulation of 22Na uptake by rat brain synaptosomes.
    Ribeiro JA; Lobo MG; Sebastião AM
    Neurochem Res; 2003 Oct; 28(10):1591-5. PubMed ID: 14570405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Conformation of adenosine deaminase in complexes with inhibitors: application of selective quenching of fluorescence emission].
    Vermishian IG; Sharoian SG; Antonian AA; Grigorian NA; Mardanian SS; Khoetsian AV; Markarian ShA
    Biofizika; 2008; 53(2):213-21. PubMed ID: 18543763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of the anti-HIV-1 activity of ddAdo by coformycin, EHNA and deaza-EHNA derivatives.
    Marongiu ME; Pani A; Tinti E; Grifantini M; Franchetti P; Cristalli G; La Colla P
    New Microbiol; 1995 Oct; 18(4):359-70. PubMed ID: 8590388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors.
    Dubey RK; Gillespie DG; Mi Z; Jackson EK
    Circulation; 1997 Oct; 96(8):2656-66. PubMed ID: 9355907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenine/ribose supply increases adenosine production and protects ATP pool in adenosine kinase-inhibited cardiac cells.
    Smolenski RT; Kalsi KK; Zych M; Kochan Z; Yacoub MH
    J Mol Cell Cardiol; 1998 Mar; 30(3):673-83. PubMed ID: 9515042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenosine deaminase inhibition enhances the inotropic response mediated by A1 adenosine receptor in hyperthyroid guinea pig atrium.
    Kemeny-Beke A; Jakab A; Zsuga J; Vecsernyes M; Karsai D; Pasztor F; Grenczer M; Szentmiklosi AJ; Berta A; Gesztelyi R
    Pharmacol Res; 2007 Aug; 56(2):124-31. PubMed ID: 17574432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.